Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Lanabecestat on the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel in Healthy Female Subjects

Trial Profile

Effect of Lanabecestat on the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel in Healthy Female Subjects

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanabecestat (Primary) ; Ethinylestradiol/levonorgestrel
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 26 Jun 2018 Planned End Date changed from 19 Oct 2018 to 1 Oct 2018.
  • 26 Jun 2018 Planned primary completion date changed from 19 Oct 2018 to 1 Oct 2018.
  • 26 Jun 2018 Planned initiation date changed from 14 Jun 2018 to 1 Jun 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top